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Artemisinin combination therapies eliminate immature Plasmodium falciparum gametocytes but not mature gametocytes,
which may persist for up to 1 month posttreatment. A single dose of primaquine, which is inexpensive and effective against ma-
ture gametocytes, could be added to further reduce the potential for posttreatment parasite transmission. Currently, we have few
data regarding the effectiveness or safety of doing so. We collected data from 21 therapeutic efficacy trials of the National Anti-
malarial Drug Resistance Monitoring System of India conducted during 2009 to 2010, wherein 9 sites used single-dose prima-
quine (0.75 mg/kg of body weight) administered on day 2 along with artesunate plus sulfadoxine-pyrimethamine (ASSP) while
12 did not. We estimated the effect of primaquine on posttreatment gametocyte clearance and the total number of gametocyte-
weeks as determined by microscopy. We compared the median area under the curve for gametocyte density and reported adverse
events. One thousand three hundred thirty-five patients completed the antimalarial drug treatment. Adjusting for region, prim-
aquine increased the rate of gametocyte clearance (hazard ratio, 1.9; 95% confidence interval [CI], 1.1 to 3.3), prevented 45%
(95% CI, 19 to 62) of posttreatment gametocyte-weeks, and decreased the area under the gametocyte density curve over the 28-
day follow-up compared to ASSP alone (P value  0.01). The results were robust to other adjustment sets, and the estimated
effect of primaquine increased during sensitivity analysis on the measurement of exposure time. No serious adverse events were
detected. In conclusion, the addition of primaquine to ASSP was effective in reducing the posttreatment presence of P. falcipa-
rum gametocytes. Primaquine was well tolerated and could be administered along with an artemisinin combination therapy as
the first-line therapy.
The primary goal of antimalarial drug therapy is to reduce mor-bidity and mortality by achieving clinical and parasitological
cure. A crucial secondary aim, however, is to reduce the infectious
reservoir and decrease malaria transmission. Gametocytes are the
sexual stage of the Plasmodium life cycle and render malaria pa-
tients infectious to mosquitoes and propagate transmission.
Treatment considerations for clearing gametocytes are distinct
from those for asexual stages because of the stage-specific actions
of antimalarial drugs, particularly for Plasmodium falciparum (1).
The chemotherapeutic control of gametocytes is largely achieved
through resolving the asexual parasitemia, which prevents the
generation of new gametocytes and limits the period of infectivity
to the circulation time of existing gametocytes. However, game-
tocytemia following treatment may be prevalent in a high propor-
tion of patients and persist for approximately up to one month
(2). Eliminating the posttreatment infectious period could pro-
vide substantial impact, particularly in countries of low to mod-
erate endemicity, where the size of the infectious reservoir is a
critical determinant of transmission (3). The potential marginal
direct and indirect costs of adjunct gametocyte-specific treatment
during the case management process make such a strategy attrac-
tive.
Artemisinin is active against all gametocyte stages barring the
fully mature stage, and this characteristic contributed to the im-
pressive declines in transmission following its widespread imple-
mentation in several countries (4). Still, in trials with artemisinin
combination therapy (ACT), mature gametocytes persisted in 10
to 30% of patients and remained infectious to mosquitoes (5–7).
Primaquine, which has no activity against asexual P. falciparum
parasites, is effective against mature gametocytes (8, 9). A single
dose of primaquine has been used as an adjunct treatment, for its
gametocytocidal effect, alongside first-line therapies in many
countries since the 1960s (10, 11). The key question for P. falcip-
arum treatment is whether a single dose of primaquine should be
added to ACTs to further reduce the transmissibility of the treated
infection (12). The Malaria Policy Advisory Committee of the
World Health Organization (WHO) noted the gametocytocidal
use of primaquine in the treatment for P. falciparum as a priority
question for operational research (13).
The goal of this study was to estimate the gametocytocidal
effect of adding primaquine to ACT in India. We conducted a
secondary analysis of data from a national network of sentinel sites
for monitoring antimalarial drug resistance. The study protocols
did not contain instructions on primaquine use, as there were no
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policy guidelines at the time of the study. The use of the drug by
some sites and not others created a natural experiment.
MATERIALS AND METHODS
Study sites and population. We utilized data from 22 trials, which had
been conducted through the National Antimalarial Drug Resistance Mon-
itoring Network of India to assess the therapeutic efficacy of artesunate
plus sulfadoxine-pyrimethamine (ASSP) for P. falciparum malaria in
2009 and 2010 (14). Among the sites, 9 used primaquine along with
ASSP while 13 used ASSP alone. We could not obtain data from 1 site
(Gadchiroli, no primaquine use) because gametocytemia was not re-
corded in case record forms and slides could not be reexamined. We
included all patients eligible for the WHO therapeutic efficacy trial pro-
tocol according to the following criteria: patients with P. falciparum
monoinfection, febrile or with a history of fever, asexual parasite density
greater than 500/l and less than 100,000/l, and willingness to consent to
follow-up (15). We excluded pregnant patients, patients with signs of
severe malaria, and patients less than 1 year of age.
Data collection. The data collection methods have been previously
described (14). Briefly, clinical and demographic information was re-
corded from each patient at enrollment. Patients were monitored during
the first 3 days of treatment and then at weekly intervals from enrollment
until day 28. Patients received ASSP (4 mg/kg artesunate for 3 days plus
25 mg sulfadoxine and 1.25 mg pyrimethamine/kg of body weight) as per
national guidelines with or without primaquine on the third day of treat-
ment (0.75 mg/kg, for a usual adult dose of 45 mg). At each follow-up visit,
a physical exam was conducted and thick and thin blood smears were
prepared. Hemoglobin measurements were not conducted for any pa-
tient. Using routine oil immersion reading at a 100 lens objective on
Giemsa-stained thick smears, slides were examined for white blood cell
(WBC) counts of up to 200 if sexual stages and/or gametocytes stages were
present or for counts of up to 1,000 WBC to declare a slide negative for
both. A count of 8,000 WBC per l of blood was assumed to obtain a final
parasite density. Thus, the estimated detection limit for gametocytes
would be 8/l, although this is likely an overestimate. The data were
double-entered into the WHO therapeutic efficacy database, and blood
slides were cross-checked by expert microscopists.
Case and predictor definitions. Primaquine therapy was the main
exposure. We obtained primaquine use information from the site physi-
cian. We defined pretreatment gametocytemia as the presence of gameto-
cytes in peripheral blood on any day between day 0 and day 2 in a patient
eligible for a therapeutic efficacy study in 2009 or 2010. We defined post-
treatment gametocyte clearance as the first day without gametocytemia
after day 2 in a patient with pretreatment gametocytemia. We defined an
event of posttreatment gametocytemia as the presence of gametocytes on
any follow-up day after day 2 in a patient eligible for the therapeutic
efficacy study in 2009 or 2010. We excluded gametocytemia at the time of
failure for patients with recrudescence or reinfection (16). For measuring
exposure time in weeks, we censored at the end of the interval. We re-
ported the data in person-weeks, instead of person-days, to enable com-
parisons with previous literature. For the measurement of posttreatment
gametocyte circulation, patients who completed the follow-up accrued an
additional week of exposure in order to incorporate the contribution of
individuals who remained positive at the end of day 28. Thus, the total
posttreatment exposure time of 32 days is congruent with biological esti-
mates of the maximum circulation time of gametocytes (2).
We compared covariates associated with gametocytemia in prior lit-
erature: age, sex, season, region, previous antimalarial drug intake, cur-
rent fever, history of fever, and asexual parasite density (17). We desig-
nated “region” using geographic clusters associated with different malaria
ecotypes, which also correspond to different transmission intensities:
western India as Gujarat, Mumbai, and Rajasthan, central India as Andhra
Pradesh, Chhattisgarh, Gadchiroli, Jharkhand, Madhya Pradesh, and
Orissa, and northeast India as the Assam, Meghalaya, and West Bengal
sites (18, 19). We classified “season” by month of enrollment: monsoon
(June to August), postmonsoon (September to November), and winter
(December and January).
Data analysis. We included in our analysis all patients who completed
treatment. Missing gametocytemia data due to withdrawal and loss to
follow-up during the treatment phase constituted less than 3% of the
overall sample. None of the covariates had missing data. We tabulated the
clinical and demographic characteristics, as well as the primary and sec-
ondary study outcomes, of patients who received and did not receive
primaquine. We calculated the mean and median gametocyte clearance
times by treatment group and compared them using the t test and rank
sum tests. We calculated the incidence, incidence rate ratios, and inci-
dence rate differences over follow-up time among the primaquine and
no-primaquine groups.
We modeled the effect of primaquine by estimating the posttreatment
clearance rates of gametocytes among patients with gametocytemia at
enrollment and by comparing the circulation of posttreatment gameto-
cyte-weeks among the entire population. We used the Cox regression with
the Efron method for ties (20) with clustered (on site) robust standard
error and the Poisson regression using general estimating equations with
unstructured correlation matrixes and robust clustered (on patient) stan-
dard error, respectively. We constructed a causal diagram of the effect of
primaquine on gametocytemia to identify adjustment sets using the DAG
program v2.1 (http://epi.dife.de/dag). Based on our diagram, adjustment
on district was sufficient to control confounding bias. However, we con-
trolled for region instead since the exposure, primaquine, did not vary by
district. To assess the robustness of the measure of effect to uncontrolled
confounding, we also produced estimates adjusted for age and parasite
density, variables strongly associated with gametocytemia, as well as esti-
mates adjusted for all covariates whose distribution differed between the
two arms (P value  0.10). We included an interaction term between
region and primaquine and assessed effect measure modification using
the Wald test (P value  0.2). We used a backwards elimination strategy to
retain confounders that changed the estimate by at least 10%. In the Cox
model, we compared the model with and without discrete (marginal) time
due to the large number of tied events and assessed the proportional
hazards assumption by examining the log[log(survival)] over time for
parallel trends between the groups. We compared the Poisson model to a
negative binomial model using a likelihood ratio test (P value  0.05) to
ensure appropriate fit with outcome dispersion.
The time at risk was measured in intervals and not continuously, i.e.,
measured on day 7, day 14, etc. A patient gametocytemic at day 7 and not
gametocytemic on day 14 may have cleared gametocytes at any point
during the interval, which potentially misclassifies the exposure time.
Based on previous studies, we conducted a sensitivity analysis assuming a
50% reduction in time at risk in a given interval among primaquine-
exposed patients. We plotted the mean area under the curve (AUC) for
gametocyte density for each group by study visit. We excluded outliers of
high pretreatment gametocyte density (maximum, 2,000/l, n  5) that
disproportionally influenced the AUC. We calculated the AUC per day
using the formula of Méndez et al. without log transformation and with
the addition of the area for gametocytemia remaining at the end of fol-
low-up (21). We compared the median AUC per day for each group using
the rank sum test. We imported the final data set into STATA (v10) and
used it for all analyses.
Study power. For gametocyte clearance, our sample size of approxi-
mately 230 patients with pretreatment gametocytemia and  of 0.05 pro-
vides more than 90% power to detect a hazard ratio of 0.5, assuming 10%
withdrawal and 80% of patients experiencing the outcome during the
follow-up period. With a no-primaquine to primaquine ratio of approx-
imately 2:1,  of 0.05, and assuming the prevalence of gametocytemia
among the exposed as 5%, we calculated more than 90% power to detect
a gametocyte-week incidence rate ratio greater than 2.
Ethical clearance. The Scientific Advisory Committee of the National
Institute of Malaria Research approved the original trials, and the Institu-
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tional Review Board of the University of North Carolina approved the
secondary analysis study.
RESULTS
During 2009 to 2010, 1,372 eligible patients were recruited among
21 sites (Fig. 1). Nine sites, where 543 patients completed treat-
ment, used primaquine, while 11 sites, where 796 patients com-
pleted treatment, did not use primaquine. Study withdrawal was
higher in the primaquine group (P value  0.02), but 11 of the 16
withdrawals were from two sites in western India where most pa-
tients were migrant workers. In each group, 2 patients missing
gametocytemia data were excluded; the final complete case popu-
lation was 1,335 patients (541 receiving primaquine and 794 not
receiving primaquine). Among treatment failures, 4 of 12 recru-
descent patients, 0 of 2 P. falciparum reinfection patients, and 0 of
6 Plasmodium vivax reinfection patients were gametocytemic at
the time of failure. The clinical, demographic, and treatment effi-
cacy as well as parasite clearance outcomes were similar between
study groups, with the exceptions of a higher proportion of males,
adults, and patients from northeast India in the primaquine-un-
exposed group (Table 1). Critically, the pretreatment gameto-
cytemia prevalence in the no-primaquine group (18%, n  141/
794) was similar to the primaquine group (20%, n  107/541).
The prevalence of gametocytemia between the arms was similar
on day 0, day 1, and day 2 and subsequently declined among the
primaquine-exposed arm starting on day 3 (Fig. 2).
Among 248 patients with pretreatment gametocytemia, the
median time to gametocyte clearance was 7 days (interquartile
range, 3 to 14) in patients who received primaquine and 14 days
(interquartile range, 3 to 28) in patients who did not (P value 
0.001). Primaquine with ASSP cleared gametocytes faster than
ASSP alone with only 3% survival of gametocytemia compared
to 23% at the end of follow-up (Fig. 3). The crude hazard ratio for
the effect of primaquine on the rate of gametocyte clearance was
2.2 (95% confidence interval [CI], 1.2 to 4.2) over 28 days. Ad-
justed for region, the addition of primaquine resulted in an in-
creased rate of gametocyte clearance 1.9 times (95% CI, 1.1 to 3.3)
that of ASSP alone over 28 days. The effect measure for prima-
quine was robust to adjusting for age and parasite density or all
covariates selected by univariate associations (data not shown).
We did not detect any modification of the effect with time or
region.
The development of posttreatment gametocytemia among pa-
tients who were pretreatment negative for gametocytemia was
lower (0.7%, 3/434) in the primaquine group than in the no-
FIG 1 Flowchart of patients eligible for treatment with primaquine from the National Antimalarial Drug Resistance Monitoring System, India, 2009 to 2010. QC,
quality control; RDT, rapid diagnostic test; D0, day zero.
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primaquine group (2.8%, 18/653) (P value  0.02). Primaquine
reduced the absolute and relative rates of posttreatment gameto-
cyte circulation among the population (Table 2). The incidence
rate ratio for the effect of primaquine on the number of posttreat-
ment gametocyte-weeks was 0.3 (95% CI, 0.2 to 0.6). Adjusted for
region, primaquine decreased the number of posttreatment ga-
metocyte weeks by 45% (95% CI, 19 to 62). The effect measure for
primaquine was robust to adjusting for age and parasite density or
all covariates selected by univariate associations (data not shown).
We did not detect any modification of the effect with region or
overdispersion of the outcome.
In our sensitivity analysis, to examine the potential bias of our
conservative assumption of midinterval gametocyte clearance in
both arms, the estimated effect of primaquine increased. The
crude and region-adjusted hazard ratios for primaquine on the
rate of gametocyte clearance were 2.8 (95% CI, 1.5 to 5.5) and 2.5
(95% CI, 1.4 to 4.3) over 28 days. The crude and region-adjusted
incidence rate ratios for primaquine on the number of gameto-
cyte-weeks were 0.2 (95% CI, 0.1 to 0.3) and 0.3 (95% CI, 0.2 to
0.4) over 28 days. The mean AUC of each group at a study visit
decreased over time compared to no primaquine (Fig. 4). The
90th to 99th percentile AUC per day was 2.2 to 79 gametocytes/l
for primaquine and 9.1 to 198 gametocytes/l for ASSP alone (P
value  0.004).
Adverse events reported during follow-up included vomiting
(8) and fever (2) in the ASSP-alone arm and vomiting (14) and
jaundice (1) in the primaquine arm. Only 5 of the 14 patients who
experienced vomiting did so on the day of primaquine adminis-
tration. The case of jaundice occurred in a 5-year-old, male child
on day 14 and self-resolved.
DISCUSSION
The addition of primaquine to ASSP reduced posttreatment
carriage of P. falciparum. The single dose of primaquine acceler-
ated gametocyte clearance by 1 week in patients who were positive
pretreatment, decreased the incidence of gametocytemia in pa-
tients who were negative pretreatment, and was well tolerated.
In those receiving only ASSP alone, the prevalence of game-
tocytemia at the end of follow-up was 5% among all patients and
24% among those initially positive for gametocytes. While the
choice of partner drug may also affect posttreatment gameto-
cytemia prevalence, as SP monotherapy is associated with in-
creased posttreatment gametocytemia (17, 22), our observations
were similar to those observed for other combination therapies
elsewhere (17, 23). We measured the effect of primaquine through
gametocyte clearance, the number of gametocyte-weeks of circu-
lation, and the area under the curve using gametocyte density over
time. By any approach, the addition of primaquine provided sub-
stantial benefit even in the presence of an artemisinin-based treat-
ment. Our sensitivity analysis suggests that our estimates were
conservative and the effect of primaquine may be larger. Other
estimates of the effect of primaquine with an ACT compared to
ACT alone include a 92% reduction in gametocyte-weeks in
Burma (24), 83% reduction in the prevalence on any day of fol-
low-up in Tanzania (25), the acceleration of gametocyte clearance
by a week in Colombia (26), and 2.4 times the rate of gametocyte
clearance in Indonesia (27). While our estimate of clearance time
TABLE 1 Demographics, clinical characteristics, and primary outcomes
by primaquine receipt status of patients from the National Antimalarial





(n  794) %
No.
(n  541)
Area Central 39.3 312 77.4 419
Western 31.4 249 22.6 122
Northeastern 29.3 233 0.0 0
Sex Male 63.7 506 49.4 267
Female 36.3 288 50.6 274
Age category (yr) 0–4 5.5 44 11.3 61
5–9 14.1 112 28.3 153
10–14 16.5 131 19.8 107
15–49 56.0 445 34.4 186
50 7.8 62 6.3 34
Asexual parasite density
(no./l)
5,000 36.5 290 35.1 190
5,000–10,000 18.1 144 15.9 86
10,000–50,000 38.8 308 38.4 208
50,000 6.5 52 10.5 57
Febrile (37.5°C) No 31.4 249 29.0 157
Yes 68.6 545 71.0 384
History of fever No 2.3 18 0.0 0
Yes 97.7 776 100.0 541
Previous drug intake No 98.4 781 97.8 529
Yes 1.0 8 1.7 9
Unknown 0.6 5 0.6 3
Primary classification ACPR 96.3 765 97.4 527
ETF 0.3 2 0.2 1
LTF 0.6 5 0.2 1
LPF 1.1 9 0.6 3
LFU 1.6 13 1.3 7
WTH 0.0 0 0.4 2
Parasite clearance
time (h)
24 58.9 468 62.5 338
24–48 27.1 215 25.3 137
48–72 11.7 93 11.3 61
72 2.0 16 0.9 5
Pretreatment
gametocytemia
No 82.2 653 80.2 434
Yes 17.8 141 19.9 107
a Abbreviations: ACPR, adequate clinical and parasitological response; ETF, early
treatment failure; LTF, late treatment failure; LPF, late parasitological failure; LFU, loss
to follow-up; WTH, withdrawal.
FIG 2 Prevalence of gametocytemia by treatment arm at each study visit
among patients from the National Antimalarial Drug Resistance Monitoring
System, India, 2009 to 2010. PQ, primaquine; arrow, administration of prim-
aquine.
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and clearance rate was similar to the estimates from the low-trans-
mission setting of the Colombian trial and Indonesia, the reduc-
tion of posttreatment gametocytemia was lower than the other
two studies in high-transmission areas. The difference in prima-
quine effectiveness could be due to the different host immunity or
pharmacokinetics of the study population, but there is also the
possibility of reduced primaquine efficacy in India. Since the ex-
tensive malaria eradication program in the 1960s, India has a long
history of primaquine use. Several studies previously reported the
frequent persistence of gametocytemia following primaquine ad-
ministration (28, 29) and the slower clearance of gametocytes after
treatment with primaquine than with a novel 8-aminoquinoline
in Western India (30).
While primaquine certainly works, several operational ques-
tions remain regarding its safety, optimal dose, and the day of
administration. The primary concern with primaquine use is
safety, given the risk of hemolysis in individuals with G6PD defi-
ciency (8). In previous single-dose primaquine trials, hemoglobin
concentrations among exposed patients were 5% lower at day 7
(recovered by the end of the month) or the mean increase over the
study was 0.3g/dl less than in patients who received only ACT (24,
25). Recent research also suggests that hemolysis may occur in
non-G6PD individuals as well, although severe anemia was rare
(31). However, hemolysis and side effects will vary by population,
and in the context of already vulnerable populations (32), more
assessments, particularly postmarketing pharmacovigilance, are
needed. We could not assess the effect of single-dose primaquine
on hemoglobin levels, as these data were unavailable. The current
dose of primaquine was determined through limited experiments
in the 1960s (10, 11). Lower, or higher, doses of primaquine may
be equally, or more, effective as well as safe—Thailand, for exam-
ple, uses a 30-mg adult dose of primaquine for gametocytocidal
therapy (33). A 4-arm, randomized study of different doses is
under way in Uganda and should help determine the trade-offs, if
any, between primaquine efficacy and safety (34). Recently, the
World Health Organization issued new guidelines for the use of
0.25 mg/kg single-dose primaquine in areas currently not imple-
menting a gametocytocide treatment (35). The recommendation
considered the risk of hemolysis with the current dose and gray
literature evidence of similar transmission-blocking efficacy using
lower doses of primaquine (36). The day of primaquine adminis-
tration varies from day 0 to day 2 with little evidence available to
guide policy. Modeling studies have suggested that later adminis-
tration, a week after ACT treatment, may have the most transmis-
sion-reducing effect (37). However, such a regimen could be op-
erationally difficult to implement.
Our study had several limitations. We used microscopy for the
measurement of gametocytemia, which is less sensitive than mo-
lecular techniques. However, in studies comparing the two meth-
ods, the latter increased the magnitude of gametocytemia but did
not alter its age structure, circulation time estimates, or other
trends (2, 38). While submicroscopic-density infections can infect
mosquitoes, the probability of infection, the proportion of mos-
quitoes infected, and the density of infection in mosquitoes are
positively correlated with gametocyte density (39, 40). Second,
primaquine use was not randomized, and the gametocyte data
were analyzed retrospectively. While we controlled for several sets
of covariates and assessed effect measure modification, confound-
ing due to unmeasured causes may bias our estimates, and the
possibility of heterogeneity of the effect cannot be excluded with
the available power (41). Third, initial gametocytemia among pa-
tients may have varied depending on the form of their recruit-
ment. The direction of bias is unclear, as active case detection
could detect infections earlier in the disease course, prior to self-
referral, or later in the disease course, after symptom attenuation,
compared to passive case detection. Finally, we used the presence
of gametocytes as a proxy for infectiousness. Infectivity is modi-
FIG 3 Clearance of gametocytes by treatment arm among patients with pre-
treatment gametocytemia from the National Antimalarial Drug Resistance
Monitoring System, India, 2009 to 2010. PQ, primaquine.
TABLE 2 Posttreatment gametocyte circulation by primaquine group
among patients from the National Antimalarial Drug Resistance




gametocytes Total IR IRR 95% CI IRD 95% CI
Days PQ 473 17,052 2.77 0.43 0.39, 0.47 0.037 0.033 to
0.041No PQ 1,620 25,019 6.48
Weeks PQ 92 2,436 3.78 0.47 0.37, 0.60 0.042 0.030 to
0.054No PQ 285 3,574 7.97
a Abbreviations: PQ, primaquine; IR, incidence rate per 100-person-time; IRR,
incidence rate ratio; IRD, incidence rate difference; CI, confidence interval.
FIG 4 Area under the curve for the mean gametocyte density by treatment
arm at each study visit among patients from the National Antimalarial Drug
Resistance Monitoring System, India, 2009 to 2010. PQ, primaquine; arrow,
administration of primaquine.
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fied by a number of factors, and its assessment through mem-
brane-feeding experiments, which are labor-intensive and time-
consuming, could preclude large, multisite trials needed for
generalizable results (42). However, recently reviewed evidence
suggests that primaquine may be effective in sterilizing gameto-
cytes prior to their clearance and underlines the importance of
measuring actual transmission (43).
We conclude that primaquine reduced the prevalence and du-
ration of posttreatment P. falciparum gametocytemia compared
to ASSP alone. Single-dose primaquine could be provided along
with ACT in India to improve malaria control. We outlined sev-
eral avenues of operational research needed for optimizing the
adjunctive use of primaquine. Future studies should use more-
sensitive detection techniques to improve estimates of gameto-
cytemia and, preferably, direct measures of transmission.
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